CRNX vs ACVA

For growth investors, Crinetics Pharmaceuticals, Inc.

(CRNX) is the stronger pick with 640. 7% revenue growth year-over-year, versus 19. 2% for ACV Auctions Inc. (ACVA). Analysts rate Crinetics Pharmaceuticals, Inc. (CRNX) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Crinetics Pharmaceuticals, Inc.

(CRNX) delivered a total return of +156. 3%, compared to -80. 4% for ACV Auctions Inc. (ACVA). Over 10 years, the gap is even starker: CRNX returned +77. 4% versus ACVA's -79. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ACV Auctions Inc.

(ACVA) is the lower-risk stock at 1. 33β versus Crinetics Pharmaceuticals, Inc. 's 1. 36β — meaning CRNX is approximately 2% more volatile than ACVA relative to the S&P 500. On balance sheet safety, Crinetics Pharmaceuticals, Inc. (CRNX) carries a lower debt/equity ratio of 5% versus 44% for ACV Auctions Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Crinetics Pharmaceuticals, Inc.

(CRNX) is pulling ahead at 640. 7% versus 19. 2% for ACV Auctions Inc. (ACVA). On earnings-per-share growth, the picture is similar: ACV Auctions Inc. grew EPS 18. 8% year-over-year, compared to -34. 1% for Crinetics Pharmaceuticals, Inc.. Over a 3-year CAGR, ACVA leads at 21. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACV Auctions Inc.

(ACVA) is the more profitable company, earning -8. 7% net margin versus -60. 5% for Crinetics Pharmaceuticals, Inc. — meaning it keeps -8. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACVA leads at -8. 1% versus -67. 1% for CRNX. At the gross margin level — before operating expenses — ACVA leads at 62. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CRNX: 99.

2% to $86. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Crinetics Pharmaceuticals, Inc.

(CRNX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (CRNX: +77. 4%, ACVA: -79. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CRNX (Healthcare) and ACVA (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.